At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Fixed-Sequence, Drug Interaction Study to Investigate the Effect of Once-Weekly Rifapentine and Isoniazid on the Pharmacokinetics of Steady-State Doravirine
In Brief
A Phase 1 clinical trial evaluating Doravirine (DOR), Rifapentine (RPT), and 1 other intervention for Latent Tuberculosis and 3 related conditions. Completed, enrolled 11 participants across 1 site.
Detailed Summary
Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes that share the same metabolic pathway as antiretroviral drugs used for those living with HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral drug when co-administered with a common anti-tuberculosis regimen of drugs.
Study Details
Timeline
Interventions
Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.